Moderna
-
Unified Patent Court Launches High-Stakes mRNA Vaccine Hearings in The Hague
The Unified Patent Court in The Hague begins key hearings in GSK’s patent infringement claims against Moderna, Pfizer, and BioNTech over mRNA vaccine technology.
-
Phase 3 Victory for Moderna and Merck’s mRNA Cancer Vaccine Signals Paradigm Shift in Personalized Oncology
Moderna and Merck’s mRNA cancer vaccine combined with Keytruda met Phase 3 goals in melanoma, driving stock surges and paving the way for FDA filing.
-
FDA Approves First mRNA Flu Vaccine for Adults 50 and Older
The FDA has approved Moderna’s mFlusiva, an mRNA-based flu vaccine for adults 50 and older, offering a faster production timeline and higher efficacy in trials.
-
FDA Approves Moderna’s mRNA-Based Flu Vaccine for Older Adults
The FDA has approved mFlusiva, Moderna’s mRNA-based flu vaccine for adults 50 and older, offering a new tool to combat seasonal influenza.
-
FDA Approves Moderna’s mRNA Flu Vaccine mFlusiva for Adults 50 and Older
The FDA has approved mFlusiva, the first mRNA-based influenza vaccine, for adults aged 50 and older, marking a major shift in vaccine technology.
-
FDA Reverses Course, Will Review Moderna’s mRNA Flu Vaccine
The U.S. Food and Drug Administration has reversed its initial refusal, agreeing to review Moderna’s mRNA flu vaccine application for the 2026/2027 flu season.
-
Dow Jones Dips 400 Points as Inflation, JPMorgan Earnings, and Trump’s Policies Sway Markets
Major U.S. stock indexes, including the Dow Jones Industrial Average, closed lower after investors assessed December’s CPI data, JPMorgan’s earnings, and President Trump’s proposals on credit card interest rates and tariffs.